Iptacopan - Novartis Pharmaceuticals
Alternative Names: FABHALTA; Iptacopan hydrochloride monohydrate - Novartis Pharmaceuticals; LNP 023; LNP023-AAB; NVP-LNP023; NVP-LNP023-AAB; NVP-LNP023-NXLatest Information Update: 25 Jul 2024
At a glance
- Originator Novartis Pharmaceuticals
- Class Anti-inflammatories; Antianaemics; Benzoic acids; Ethers; Eye disorder therapies; Indoles; Piperidines; Small molecules; Urologics
- Mechanism of Action Complement factor B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Paroxysmal nocturnal haemoglobinuria
- Preregistration IgA nephropathy
- Phase III Atypical Haemolytic Uraemic Syndrome; Membranoproliferative glomerulonephritis
- Phase II Age-related macular degeneration; Lupus nephritis; Membranous glomerulonephritis
- Discontinued Autoimmune haemolytic anaemia; Idiopathic thrombocytopenic purpura
Most Recent Events
- 18 Jul 2024 Registered for Paroxysmal nocturnal haemoglobinuria in China (PO) before July 2024
- 18 Jul 2024 Registered for Paroxysmal nocturnal haemoglobinuria in European Union (PO) before July 2024
- 18 Jul 2024 Novartis plans to submit regulatory applications for Membranoproliferatve glomerulonephritis the US FDA and EMA in H2 2024